AG-014699 kinase inhibitor product blog
Tags: Kinase Inhibitor; AG-014699; AG-014699 kinase inhibitor;
The AG-014699 n/a (Catalog #MBS8506149) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase.To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given inhibitor. We\'ve tested the AG-014699 (PF-01367338) with the following immunoassay(s):
Testing Data
Rucaparib (AG-014699, PF-01367338) is a PARP inhibitor (Ki, 1.4 nmol/L) with outstanding in vivo chemosensitization potency, which is greater chemosensitization of temozolomide at a dose of 1 mg/kg than could be achieved with AG14361 at 10 mg/kg. Even a 10-fold lower dose of AG14447 (0.1 mg/kg) resulted in a 50% increase in the temozolomide-induced tumor growth delay. Rucaparib (AG-014699, PF-01367338), the phosphate salt of AG14447, which has improved aqueous solubility, has been selected for clinical trial. Rucaparib (AG-014699, PF-01367338) is a tricyclic indole poly(ADP-Ribose) polymerase (PARP) inhibitor with potential antineoplastic activity. PARP-1 inhibitor Rucaparib (AG-014699, PF-01367338) blocks base excision repair mediated by PARP 1 on single strand breaks and may be particularly efficacious in inducing apoptosis in breast cancer associated gene-1 and-2 (BRCA1/2) deficient tumor cells.].
Solubility: DMSO >=84mg/mL - Water >=60mg/mL - Ethanol >=7mg/mL. Formula: C19H18FN3O.H3PO4
CAS Number: 459868-92-.